Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
This study is testing a treatment called adenovirus-specific cytotoxic T-lymphocytes (CTLs) for people with adenovirus infections that haven't responded to standard antiviral medicines. These CTLs are special immune cells designed to fight the adenovirus. They are collected from a related donor (either a perfect match or a partial match) and given intravenously (into a vein). This study is for children, adolescents, and young adults (ages 1 month to 79 years) who have adenovirus infections after a stem cell transplant, with a primary immune deficiency, or after an organ transplant. The main goals are to see how safe the treatment is and if it helps clear the infection. The study plans to enroll 20 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be checked for 12 weeks after each infusion, and treatment response will be checked 12 weeks after the last infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
At a glance
Conditions
Where it's being run
10 sites across 8 statesStudy leadership
- Mitchell Cairo, MD · PRINCIPAL_INVESTIGATOR · New York Medical College
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]12 weeks after each infusion
Patients will be followed for adverse events following each infusion of ADV CTLs
- Incidence of Response to Treatment (Efficacy)12 weeks after last infusion
Patients will be followed for improvement in viral infection by monitoring ADV PCR weekly for response to treatment with CTLs